Novo Nordisk scores a win for semaglutide in obesity, potentially setting up a next-gen battle with Eli Lilly
Novo Nordisk pulled a highly anticipated win for its GLP-1 therapy semaglutide in obesity on Friday, becoming the first company to get a chronic weight management drug for adults past regulators since 2014.
Semaglutide — marketed for type 2 diabetes as Ozempic — was first approved in 2017. The blockbuster generated $3.4 billion in sales last year, surpassing Novo’s older GLP-1 drug Victoza. It’ll be marketed as Wegovy in obesity, and Novo expects to start rolling it out later this month.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,500+ biopharma pros reading Endpoints daily — and it's free.